Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 50 to 70

Low-Volume PENG Block With Dexamethasone After Hip Replacement

Official title: Low-Volume PENG Block With Dexamethasone Versus Standard-Volume PENG Block for Postoperative Analgesia and Quadriceps Function After Total Hip Arthroplasty

Run by Ain Shams University · NCT07855341 · Data updated 2026-11-12

This trial tests whether a smaller PENG block with dexamethasone provides similar pain relief but preserves quadriceps strength after hip replacement, compared with the standard-volume PENG block.

Quick facts

PhasePhase 4
Study typeInterventional
Ages50 Years to 70 Years
SexAll
Enrollment60 (estimated)
SponsorAin Shams University
Academic / other
Locations1 site (Cairo, Cairo Governorate)
StatusRecruiting
StartedOctober 15, 2026
Main results expectedAugust 31, 2027
Study endsSeptember 14, 2027
Registry record updatedOctober 16, 2026
Trial IDNCT07855341 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 50-70 undergoing elective primary unilateral total hip arthroplasty under spinal anesthesia who are ASA I or II.

Probably not a fit

Patients who do not respond to dexamethasone optimization or who experience longer analgesic duration with low-volume blocks may see limited benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional phase 4 study compares two ultrasound-guided PENG block regimens in adults undergoing primary unilateral total hip arthroplasty under spinal anesthesia. The low-volume approach uses 10 mL of bupivacaine 0.25% with 4 mg dexamethasone, aiming to reduce spread to the femoral nerve and preserve quadriceps function, while potentially shortening analgesic duration. The standard-volume approach uses 20 mL of bupivacaine 0.25% without specified corticosteroid optimization beyond multimodal analgesia. Outcomes focus on time to first rescue analgesia and postoperative pain and mobility, with attention to opioid-sparing effects and motor preservation. Background context notes that PENG blocks target articular branches around the hip and have shown analgesic benefits, but motor-sparing claims with higher volumes may not always hold.

Why it matters

Potential benefit: If successful, patients may experience effective pain control with better quadriceps strength, enabling earlier mobilization after hip replacement.

How similar studies have gone: Previous analyses and meta-analyses suggest PENG blocks reduce opioid needs and pain, but the impact of low-volume, dexamethasone-augmented regimens requires confirmation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Physical status ASA I or II.
* Age 50-70 years.
* Patients scheduled for elective primary unilateral total hip arthroplasty under spinal anaesthesia.
* No sex predilection.

Exclusion Criteria:

* Patient refusal.
* Physical status ASA III or above.
* Contraindications to spinal anaesthesia (coagulopathy, local infection at injection site, raised intracranial pressure).
* Revision or bilateral total hip arthroplasty.
* Known allergy or hypersensitivity to study drugs (bupivacaine, dexamethasone) or to any component of the multimodal analgesic regimen (paracetamol, nalbuphine).
* Pre-existing neuromuscular disease, lower-limb motor deficit, or neuropathic pain syndrome.
* Uncontrolled diabetes mellitus (HbA1c \> 8% or fasting blood glucose \> 180 mg/dL) or any contraindication to corticosteroids.
* Cognitive impairment precluding pain and motor assessment, or chronic opioid use.
* Body mass index greater than 40 kg/m2 precluding adequate ultrasound visualization.

Where it's running

  • Ain Shams University Hospitals (El Demerdash Hospital)
    Cairo, Cairo Governorate, Egypt
    Recruiting

Study contacts

  • Principal investigator: Mohamed F Morsi, M.B., B.Ch., M.Sc. — Faculty of Medicine, Ain Shams University
  • Study coordinator: Mohamed F Morsi, M.B., B.Ch., M.Sc.
  • Email: MohamedMorsi@med.asu.edu.eg
  • Phone: +201116618163

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.